Skip to content

Trial Summary

This study is designed to test the safety and potential benefit of adding an existing drug used for bone protection (denosumab) to a new immune stimulating drug (pembrolizumab).

Acronym:

ANZUP1601

ACTRN/NCT /ethics:

ACTRN12618000132246

Scientific title:

Denosumab and Pembrolizumab in clear cell renal carcinoma

Sponsor / Cooperative group:

Merck Sharp & Dohme Corp.

Trial & Patient Characteristics

Cancer TypeKidney
Trial TypeTreatment
PhasePhase II
Age Range18 years and older
SexAll
Tumour Stream -
Cancer StageAll stages
Anticipated Start Date2017-12-12
Anticipated End Date2022-12-31

Participating Hospitals

HospitalFlinders Medical Centre
Clinical Trial CoordinatorHannah Adelson
EmailHannah.adelson@sa.gov.au
Phone08 8206 4835
Principal InvestigatorDr Sina Vatandoust
Recruitment StatusRecruiting